|
US2003124187A1
|
|
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
|
AU2768402A
|
|
Use of glucose uptake enhancer for reducing apoptosis
|
|
US2002099080A1
|
|
Indole derivatives useful A.O. for the treatment of osteoporosis
|
|
AU6571400A
|
|
Pharmaceutical formulation comprising amoxycillin and clavulanate
|
|
FR2797588A1
|
|
Pharmaceutical formulation based on amoxycillin and clavulanate
|
|
GB0019523D0
|
|
Novel use
|
|
GB0019524D0
|
|
Novel use
|
|
GB0019410D0
|
|
Novel use
|
|
GB0019084D0
|
|
Pharmaceutical formulation
|
|
GB0015490D0
|
|
Novel formulations
|
|
GB9923933D0
|
|
Novel pharmaceutical
|
|
GB9920150D0
|
|
Pharmaceuticals formulation
|
|
GB9919840D0
|
|
Pharmaceutical formulation
|
|
WO9947564A1
|
|
Fas-associated polypeptides
|
|
CZ20002341A3
|
|
Indole derivatives suitable for treating osteoporosis
|
|
WO9933822A1
|
|
Indole derivatives useful a.o. for the treatment of osteoporosis
|
|
CA2245997A1
|
|
Novel compounds
|
|
EP0911341A1
|
|
Adenine nucleotide translocator
|
|
CA2241433A1
|
|
Novel compounds
|
|
JPH11113583A
|
|
New compound
|
